Work

News Beyond Our Pages

Year: 2018

Type: article

Abstract: A mainstay in the pharmacologic treatment of asthma is stepwise escalation from short-acting β2-agonist monotherapy to additional therapy with long-acting β2-agonists (LABAs) and inhaled glucocorticoids. The importance of long-acting muscarinic antagonists (LAMAs) has been accepted by guidelines, such as the Global Initiative for Asthma. Sobieraj et al have performed 2 systematic reviews and meta-analyses regarding the management of asthma. The first review (JAMA 2018;319:1473-84; https://doi.org/10.1001/jama.2018.2757) focused on the efficacy of LAMAs as an add-on therapy to inhaled glucocorticoids in adolescent and adult patients with uncontrolled asthma.

Source: Journal of Allergy and Clinical Immunology

DOI: 10.1016/j.jaci.2018.05.010

Authors: Marc E. Rothenberg, Jean Bousquet

Language: English

Topic: Asthma and respiratory diseases

Subfield: Physiology (medical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,900

OpenAlex ID: W4246364970

FWCI:

Cites:

Cited by:

Related to: 10